AGP Picks
View all

Colorado Health Reporter
Provided by AGP

Colorado Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Colorado Health Reporter.

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

Press releases published on June 1, 2026

Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence
Jun. 1, 2026

Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence

Indeterminate GlobeNewswire
Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development
Jun. 1, 2026

Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development

Indeterminate GlobeNewswire
Ardena appoints Ariane de Ganck as Chief Scientific Officer
Jun. 1, 2026

Ardena appoints Ariane de Ganck as Chief Scientific Officer

Indeterminate GlobeNewswire
Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions
Jun. 1, 2026

Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions

Indeterminate GlobeNewswire
Inspire Launches GLP-1 Connect: A Free Community for Real Conversations About GLP-1 Therapies
Jun. 1, 2026

Inspire Launches GLP-1 Connect: A Free Community for Real Conversations About GLP-1 Therapies

Indeterminate GlobeNewswire
ALS Canada rallies around progress in research and a call for continued action this ALS Awareness Month
Jun. 1, 2026

ALS Canada rallies around progress in research and a call for continued action this ALS Awareness Month

Indeterminate GlobeNewswire
La Société canadienne de la SLA met en avant les avancées de la recherche et appelle à poursuivre la lutte pendant ce mois de la sensibilisation à la SLA
Jun. 1, 2026

La Société canadienne de la SLA met en avant les avancées de la recherche et appelle à poursuivre la lutte pendant ce mois de la sensibilisation à la SLA

Indeterminate GlobeNewswire
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Jun. 1, 2026

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Indeterminate GlobeNewswire
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
Jun. 1, 2026

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire
MDA Expands 2026 Engage Symposium Series, Bringing the Neuromuscular Community Together in Four U.S. Cities
Jun. 1, 2026

MDA Expands 2026 Engage Symposium Series, Bringing the Neuromuscular Community Together in Four U.S. Cities

Indeterminate GlobeNewswire
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Jun. 1, 2026

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Indeterminate GlobeNewswire
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
Jun. 1, 2026

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

Indeterminate GlobeNewswire
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
Jun. 1, 2026

LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

Indeterminate GlobeNewswire
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Jun. 1, 2026

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Indeterminate GlobeNewswire
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
Jun. 1, 2026

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

Indeterminate GlobeNewswire
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
Jun. 1, 2026

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Indeterminate GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
Jun. 1, 2026

Wave Life Sciences to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire
Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome
Jun. 1, 2026

Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome

Indeterminate GlobeNewswire
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Jun. 1, 2026

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Indeterminate GlobeNewswire
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
Jun. 1, 2026

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

Indeterminate GlobeNewswire
Show More

Share this page:

Sign up for:

Colorado Health Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.